Stifel Nicolaus Downgrades Synta Pharma. (SNTA) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
BMO Capital Downgrades Synta Pharma. (SNTA) to Underperform
March 12, 2014 6:25 AM EDTBMO Capital analyst Jim Birchenough downgraded Synta Pharma. (NASDAQ: SNTA) from Market Perform to Underperform and slashed his price target to $1 after weak Q1 results. The analyst notes limited cash, CEO departure and questionable direction.
Birchenough said, "With the extension of the timelines... More
Synta Pharma (SNTA) Ganetespib Selected for Study in I-SPY 2 TRIAL
March 11, 2014 7:05 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) and QuantumLeap Healthcare Collaborative announced that Syntas lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting (prior to surgery).
The I-SPY 2 TRIAL... More
